A multi-centred, randomized, double blinded and placebo controlled treatment effectiveness Phase III clinical trial for early stage Parkinson's disease patients
Phase of Trial: Phase III
Latest Information Update: 16 Apr 2018
At a glance
- Drugs Rotigotine (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- 16 Apr 2018 New trial record
- 12 Apr 2018 According to a Luye Pharma media release, the company has reached a consensus with the centre for drug evaluation (CDE) of China Food and Drug Administration and is exempted from Phase II dosage exploration clinical trials for LY03003 and can directly commence Phase III trials.
- 10 Apr 2018 According to a Luye Pharma media release, the company has obtained the approval from the China Food and Drug Administration (CFDA) to proceed with this trial.